For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Chuikyo OKs NHI Price Listing of 14 APIs/15 Products
November 20, 2014
- MHLW Will Rack Its Brain about How to Eke Out Social Security Funds: Shiozaki
November 20, 2014
- 3 Straight Years of NHI Price Cuts Loom as Abe Delays Sales Tax Hike, Eyes Now Turned to 2019 and Beyond
November 19, 2014
- MHLW OKs 4 Products Including New Indication for Spiriva
November 19, 2014
- Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients
November 18, 2014
- Only Advantage of Authorized Generics is that “They Can Be Sold Earlier”: Prof. Ogata
November 18, 2014
- PAFSC 2nd Committee to Discuss Novartis’s Secukinumab on Nov. 28
November 18, 2014
- Editor’s Pick: Five Healthcare News Headlines for Nov. 4 - 14
November 17, 2014
- MHLW Official Says Penalty Rule Needs Review, Frowns on Sanguine Outlook for Annual Drug Price Cut
November 17, 2014
- PMDA to Accept All Requests for Generic Drug Face-to-Face Consultations
November 17, 2014
- MHLW to Report Poteligeo’s Additional Indication of Untreated CCR4-Positive ATL to PAFSC 2nd Committee on Nov. 28
November 17, 2014
- PMDA Looks to New Pre-Application Meetings to Shed Review Time
November 14, 2014
- New Japan NIH Head Asks Pharma Industry to Suggest Ideas for Benefit of Japanese People
November 13, 2014
- PMDA to Expand Consultation Services for Clinical Trials Initiated by Academia
November 12, 2014
- Blue, Yellow Letters to Cover Regenerative Medicines
November 11, 2014
- MHLW Mulls Creating Rules under Law for Patient-Initiated Mixed-Care System
November 11, 2014
- PAFSC First Committee to Discuss Takeda’s Vonoprazan on Nov. 21
November 11, 2014
- US FDA Withdraws Tentative Approvals for 2 Generic Drugs of Ranbaxy
November 11, 2014
- 5 Experts Likely to Review Regenerative Medicines for Expedited Senshin-Iryo Scheme
November 10, 2014
- Health Ministry Panel Includes Legal Regulations for Clinical Research in Draft Outline
November 10, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…